• Diabetes/Endocrine/Metabolic Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PUK22 A RETROSPECTIVE COHORT STUDY ON CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND DISEASE OUTCOMES IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES USING A JAPANESE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • Drugs Public Health

    Nov 1, 2019, 00:00

  • PDB34 A PERSONALIZED SCREENING STRATEGY FOR DIABETIC RETINOPATHY: A COST-EFFECTIVENESS PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB36 EVALUATING THE IMPACT OF INSULIN PRICE FLUCTUATION IN THE USA ON THE HEALTHCARE EXPENDITURE IN T2DM

    Nov 1, 2019, 00:00

  • PBI93 CHANGE IN PERSISTENCE OVER TIME OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL OBSERVATIONAL LONGITUDINAL POPULATION STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PCV44 COST ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ROSUVASTATIN AND EZETIMIBE IN THE GREEK SETTING

    Nov 1, 2019, 00:00

  • PNS321 EASINESS AND RELIABILITY IN ESTIMATING PATIENT-LEVEL SURVIVAL DATA FROM KAPLAN-MEIER CURVES

    Nov 1, 2019, 00:00

  • PCV149 UNHEALTHY WEEKENDS OR MONDAY BLUES? INVESTIGATING THE WEEKLY PATTERN OF STROKES

    Nov 1, 2019, 00:00

  • PCN223 A BUDGET IMPACT ANALYSIS OF A COMMUNITY-BASED SUPPORT CENTRE FOR CANCER PATIENTS AND SURVIVORS

    Nov 1, 2019, 00:00

  • PDG69 DEVELOPMENT OF LISTS OF TOPICAL ANTIFUNGAL DRUGS INCLUDED INTO THE ALL EDITIONS OF STATE FORMULARY OF UKRAINE

    Nov 1, 2019, 00:00

  • PNS224 SHOULD THE PATIENT VOICE HAVE AN ACTIVE ROLE IN HTA DECISION-MAKING? A PAG CONSENSUS ANALYSIS IN GREECE

    Nov 1, 2019, 00:00

  • PND6 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WITH UP TO ONE PREVENTIVE MIGRAINE PROPHYLAXIS TREATMENT IN THE PAST

    Nov 1, 2019, 00:00

  • Alternative Medicine Public Health

    Nov 1, 2019, 00:00

  • PMU121 CRITICAL REVIEW OF VALIDATION STUDIES OF ARTIFICIAL INTELLIGENCE TECHNOLOGIES APPLIED IN MEDICINE DURING THE LAST FIVE YEARS

    Nov 1, 2019, 00:00

  • PRO156 APPROACHES TO THE COLLECTION OF UTILITY VALUES FOR RARE DISEASES

    Nov 1, 2019, 00:00

  • PMS2 EXAMINATION OF A SPORT-SPECIFIC DYNAMIC CORE STABILITY PROGRAMME AMONG FEMALE ACROBATIC ROCK AND ROLL DANCERS

    Nov 1, 2019, 00:00

  • PNS33 PUBLICATION TREND AND CITATION ANALYSIS OF ARTICLES PUBLISHED IN "VALUE IN HEALTH” BETWEEN 1998-2019

    Nov 1, 2019, 00:00

  • PGI50 THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS IN JAPAN

    Nov 1, 2019, 00:00

  • PNS283 STATUS QUO OF CLAIMS DATA ANALYSES IN THE GERMAN AMNOG HTA PROCESS - DID QUALITY IMPROVE?

    Nov 1, 2019, 00:00

  • PCN213 COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN

    Nov 1, 2019, 00:00

  • PBI56 SUSTAINABLE BIOSIMILAR PROCUREMENT IN EUROPE: A REVIEW OF CURRENT POLICIES AND THEIR POTENTIAL IMPACT

    Nov 1, 2019, 00:00

  • PCN175 BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF MIDOSTAURIN FOR FLT3-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM (BPHS).

    Nov 1, 2019, 00:00

  • PMU120 CRITICAL REVIEW OF VALIDATION STUDIES OF NATURAL LANGUAGE PROCESSING TECHNIQUES APPLIED TO INFORMATION FROM ELECTRONIC MEDICAL RECORDS DURING THE LAST 5 YEARS

    Nov 1, 2019, 00:00

  • PNS212 AIFA'S NEW INNOVATIVENESS DESIGNATION: DRIVERS FOR AWARD AND COMPARISON TO FRENCH HTA ASSESSMENTS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV116 USING ADMINISTRATIVE CLAIMS DATA TO ESTIMATE THERAPEUTIC INTENSITY IN MEDICALLY MANAGED HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00

  • PMD59 COST-EFFECTIVENESS EVALUATION OF PHACOEMULSIFICATION PLATFORMS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCN341 HOW INFLUENTIAL IS BUDGET IMPACT IN DETERMINING PRICING FOR ONCOLOGY PRODUCTS?: A REGRESSION ANALYSIS

    Nov 1, 2019, 00:00

  • PCN145 COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB IN ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION IN FRANCE

    Nov 1, 2019, 00:00

  • PMD50 COMPARING THE ABILITY OF TWO INNOVATIVE OSTOMY BAGS TO PREVENT BALLOONING IN A REAL-LIFE SETTING

    Nov 1, 2019, 00:00

  • PRO118 WHAT IS THE IMPACT OF ORPHAN DRUG RE-ASSESSMENTS IN GERMANY ON THEIR ADDITIONAL BENEFIT AND PRICE?

    Nov 1, 2019, 00:00

  • PUK8 THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING DISTRAL RENAL TUBULAR ACIDOSIS (DRTA) IN THE UK HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PMU33 EPIDEMIOLOGY OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR): EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN155 AN ECONOMIC SYSTEMATIC LITERATURE REVIEW FOR UNTREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PCN461 CHARACTERIZATION OF THE CARE PATHWAYS OF PATIENTS WITH MERKEL CELL CARCINOMA IN FRANCE

    Nov 1, 2019, 00:00

  • CL2 SYSTEMATIC REVIEW AND METANALYSIS ON THE IMPACT OF MULTI-DRUG RESISTANT BACTERIA ON ECONOMIC AND CLINICAL OUTCOMES OF HEALTHCARE ACQUIRED INFECTIONS

    Nov 1, 2019, 00:00

  • PCN368 ADVANCED NMA TECHNIQUES IN NICE STA SUBMISSIONS

    Nov 1, 2019, 00:00

  • PBI23 A COST ANALYSIS OF HEMOSTATIC SURGICAL RESOURCES ASSOCIATED WITH A NOVEL FIBRIN SEALANT COMPARED TO STANDARD OF CARE ACROSS SURGERY TYPES

    Nov 1, 2019, 00:00

  • PIH37 ASSESSMENT OF PRECLINICAL MARKERS "MOBILITY LIMITATIONS” AND "COGNITIVE IMPAIRMENT” AMONG GERIATRIC INPATIENTS: EVIDENCE FROM THE CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PSY57 PATTERNS OF PHARMACOLOGICAL TREATMENT IN ADULT PATIENTS WITH ATOPIC DERMATITIS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PIH55 A MULTIVARIATE APPROACH TO EXPLORE THE DRIVERS OF MEDICINE ACCEPTABILITY IN PEDIATRICS

    Nov 1, 2019, 00:00

  • PMS15 REAL-WORLD EFFECTIVENESS OF SECUKINUMAB FOR PSORIATIC ARTHRITIS PATIENTS: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN

    Nov 1, 2019, 00:00

  • PMH18 PREVENTING MENTAL HEALTH CONDITIONS IN CHILDREN AND YOUNG ADULTS: A REVIEW OF THE COSTS OF COMPLEX INTERVENTIONS

    Nov 1, 2019, 00:00

  • PCN448 IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OS

    Nov 1, 2019, 00:00

  • PNS253 IS THERE STILL A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS? UPDATED ANALYSIS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMU60 INCENTIVE STRUCTURES OF ADDITIONAL PAYMENTS FOR NEW TECHNOLOGIES IN INPATIENT CARE: DOES IT WORK?

    Nov 1, 2019, 00:00

  • Artificial Intelligence Studies

    Nov 1, 2019, 00:00

  • PMS14 FLARE QUESTIONNAIRE FOR RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND RECURRENCE IDENTIFICATION IN CLINICAL RESEARCH

    Nov 1, 2019, 00:00

  • PND69 COSTS OF MULTIPLE SCLEROSIS IN DENMARK: INFORMAL CAREGIVER'S PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMS48 270-DAYMORTALITY AND ITS PREDICTORS IN MEN WITH CONTRALATERAL HIP FRACTURE AFTER FEMORAL NECK FRACTURE

    Nov 1, 2019, 00:00

  • PIH6 METABOLICS SYNDROME AND COMPLICATIONS PREGNANT WITH PCOS

    Nov 1, 2019, 00:00

  • PIN119 NOVEL PRICING OF NEW ANTIMICROBIALS – HOW CAN WE PRICE TO REFLECT THE VALUE TO SOCIETY AND THE MANUFACTURER?

    Nov 1, 2019, 00:00

  • PCN224 TREATMENT BENEFIT DISCONTINUATION: COMPARISON OF A PARTITIONED SURVIVAL ANALYSIS AND A SEMI-MARKOV MULTI-STATE MODEL APPROACH USING AN ONCOLOGY CASE STUDY

    Nov 1, 2019, 00:00

  • PBI63 IMPACT OF TOCILIZUMAB SUBCUTANEOUS INJECTION COMMERCIALIZATION ON PRACTICES IN THE PUBLIC HOSPITALS OF PARIS

    Nov 1, 2019, 00:00

  • PMH37 COMPARING THE QUALITY OF SLEEP AMONGST BENZODIAZEPINE DEPRESCRIBED GROUP AND CONTINUING GROUP

    Nov 1, 2019, 00:00

  • PRO15 ORPHAN DRUG METHODOLOGY CHALLENGES IN THE DANISH HTA PROCESS - MEDICINRAADET AND THE HURDLES TO SHOWING CLINICAL BENEFIT IN SMALL PATIENT POPULATIONS

    Nov 1, 2019, 00:00

  • PDB71 ASSOCIATION OF SEVERE HYPOGLYCEMIA WITH ALL-CAUSE MORTALITY AND COMPLICATIONS AMONG PATIENTS WITH DIABETES MELLITUS IN CHINA

    Nov 1, 2019, 00:00

  • PNS94 ESTIMATING MISSING BASELINE SERUM CREATININE FOR ACUTE KIDNEY INJURY DIAGNOSIS IN HOSPITALISED PATIENTS

    Nov 1, 2019, 00:00

  • PRO82 REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN

    Nov 1, 2019, 00:00

  • PBI48 EQUALITY IN ACCESS TO DMARDS IN TURKEY

    Nov 1, 2019, 00:00

  • PRS52 DEVELOPMENT OF A NOVEL ECONOMIC MODELING APPROACH FOR ASTHMA

    Nov 1, 2019, 00:00

  • PNS281 DO SPANISH TPRS AFFECT THE NATIONAL PRICING AND REIMBURSEMENT OF DRUGS?

    Nov 1, 2019, 00:00

  • PNS43 ORGANISING THE LITERATURE IN A SYSTEMATIC LITERATURE REVIEW USING FACTOR ANALYSIS

    Nov 1, 2019, 00:00

  • PDB24 REAL WORLD DATA ANALYSIS OF HEALTHCARE RESOURCE USE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN13 HANNA – REAL-WORLD EVIDENCE FROM A GERMAN, PROSPECTIVE, NON-INTERVENTIONAL STUDY WITH NIVOLUMAB IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN365 TITLE: REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS307 THE COMBINED USE OF TREEAGE SOFTWARE TO ACCELERATE MARKOV MODEL CONSTRUCTION WITHIN AN EXCEL USER INTERFACE

    Nov 1, 2019, 00:00

  • PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

    Nov 1, 2019, 00:00

  • Medical Devices - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PMS66 A COMPARISON OF STATISTICAL METHODS USED IN TRIAL-BASED ECONOMIC EVALUATIONS; DOES IT MATTER WHICH METHOD IS USED?

    Nov 1, 2019, 00:00

  • PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY

    Nov 1, 2019, 00:00

  • PIN3 SOFOSBUVIR/VELPATASVIR VS GLECAPREVIR/PIBRENTASVIR IN GENOTYPE 3 HEPATITIS C VIRUS INFECTED PATIENTS

    Nov 1, 2019, 00:00

  • PNS362 EQ-5D-5L DATA FOR BULGARIAN POPULATION

    Nov 1, 2019, 00:00

  • PRO6 TRANSLATION AND LINGUISTIC VALIDATION OF THE HEMOPHILIA QUALITY OF LIFE (HAEMO-QOL-A) QUESTIONNAIRE FOR USE WITH HEMOPHILIA PATIENTS

    Nov 1, 2019, 00:00

  • PCV114 FEASIBILITY OF USING REAL WORLD EVIDENCE TO INFORM DECISIONS ON CONDUCTING A COST EFFECTIVENESS ANALYSIS: AN EXAMPLE OF STROKE RISK REDUCTION THERAPIES IN ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIO ...

    Nov 1, 2019, 00:00

  • PIH50 MODERN APPROACH TO CREATION OF DONOR BREAST MILK BANKS IN UKRAINE

    Nov 1, 2019, 00:00

  • PNS165 THE USE OF MANAGED ENTRY AGREEMENTS FOR ADVANCED THERAPIES IN EU5

    Nov 1, 2019, 00:00

  • PRO148 PSYCHOMETRIC EVALUATION OF A MODIFIED VISUAL FUNCTION QUESTIONNAIRE (MVFQ-25) USING DATA FROM A PHASE III OPEN-LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH INHERITED RETINAL DYSTROPHY CAUSED BY BIALLELIC RPE65 MUTATIONS

    Nov 1, 2019, 00:00

  • Drugs Generics - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN314 POPULATION BASED STUDY OF BASELINE BONE DENSITY SCREENING IN PROSTATE CANCER PATIENTS TREATED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY

    Nov 1, 2019, 00:00

  • PBI2 COMPARISON OF A NEW FIBRIN SEALANT TO CURRENT HEMOSTASIS METHODS IN PERIPHERAL VASCULAR SURGERY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PCN225 TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREA ...

    Nov 1, 2019, 00:00

  • PCN148 COST-UTILITY OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1+ NSCLC PATIENTS: AN AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE

    Nov 1, 2019, 00:00

  • PSY48 DO CLINICAL AND DEMOGRAPHIC CHARACTERISTICS AFFECT PATIENT PREFERENCE HETEROGENEITY FOR PSORIASIS TREATMENTS? RESULTS FROM A DISCRETE-CHOICE EXPERIMENT IN A MULTICOUNTRY STUDY

    Nov 1, 2019, 00:00

  • PRO20 PROJECT HERCULES: A PARADIGM SHIFT IN THE DEVELOPMENT OF COST-EFFECTIVENESS MODELS IN RARE DISEASES

    Nov 1, 2019, 00:00

  • PND122 HEALTHCARE RESOURCE UTILIZATIONS AND COSTS AMONG PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - A COMPARISON OF PATIENTS WITH AND WITHOUT UPPER LIMB FUNCTION IMPAIRMENT

    Nov 1, 2019, 00:00

  • PCN10 A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

    Nov 1, 2019, 00:00

  • PMU47 ORPHAN DRUG DESIGNATION: NO IMPACT ON PR PROCESS TIMING IN ITALY

    Nov 1, 2019, 00:00

  • PNS325 GAME THEORY IN THE HEALTHCARE LITERATURE:A SYSTEMATIC REVIEW FOCUSING ON NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PDB94 PREDICTIVE MODELS USING MACHINE LEARNING FOR MICROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PND64 EPIDEMIOLOGY OF CHRONIC MIGRAINE: A REAL-WORLD STUDY IN PRIMARY CARE IN ITALY

    Nov 1, 2019, 00:00

  • PCN97 DIRECT COSTS ASSOCIATED WITH NEUTROPENIA AND FEBRILE NEUTROPENIA AS ADVERSE EVENTS OF CHEMOTHERAPY IN SERBIAN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PNS131 DO THE EVOLVING MARKET ACCESS POLICY DYNAMICS AND INCREASING IMPORTANCE OF CLINICAL AND HEALTH ECONOMIC EVIDENCE REPRESENT THE NEXT BIG OPPORTUNITY FOR PHARMA TO DEMONSTRATE VALUE IN CHINA?

    Nov 1, 2019, 00:00

  • PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER

    Nov 1, 2019, 00:00

  • PIN137 THE USE OF MULTI-YEAR AGE GROUPS IN VACCINATION MODELS BIAS THE RESULTS FOR VACCINATED INDIVIDUALS

    Nov 1, 2019, 00:00

  • PCN520 CLINICAL AND ECONOMIC EVALUATIONS OF MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PCV102 PRESCRIPTION PATTERN EUROPE

    Nov 1, 2019, 00:00

  • PGI38 ASSESSMENT OF PROPULSIVES CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Nov 1, 2019, 00:00

  • PRO54 ECONOMIC BURDEN OF CARE AND TREATMENT OPTIONS FOR PATIENTS WITH RETT SYNDROME: TWO SYSTEMATIC LITERATURE REVIEWS

    Nov 1, 2019, 00:00

  • PIT4 PATIENT CHARACTERISTICS AND HEALTHCARE UTILIZATION FOLLOWING COMMINUTED GUSTILO-ANDERSON TYPE III FRACTURES

    Nov 1, 2019, 00:00

  • PMH21 COST-EFFECTIVENESS OF THE PREDICT TEST: RESULTS AND LESSONS LEARNED FROM A EUROPEAN MULTINATIONAL DEPRESSION TRIAL

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS393 POPULATION NORMS WITH THE ICECAP-A AND ICECAP-O CAPABILITY MEASURES IN HUNGARY

    Nov 1, 2019, 00:00

  • Surgery - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PMS25 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE KNEE AND LOWER LEG IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PMU110 OPTIMIZING EARLY ACCESS THROUGH ITALY'S PHARMACEUTICAL INNOVATION SYSTEM: KEY SUCCESS FACTORS FOR ATTAINING INNOVATIVE AND CONDITIONALLY INNOVATIVE STATUS

    Nov 1, 2019, 00:00

  • PIN79 ECONOMIC EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS IN CHINESE HOSPITALS

    Nov 1, 2019, 00:00

  • PIH45 UPTAKE OF ANTENATAL CARE SERVICES AMONG HIV POSITIVE WOMEN ATTENDING AN URBAN HIV CLINIC IN UGANDA

    Nov 1, 2019, 00:00

  • PMH65 COMPARISON OF CHARACTERISTICS AND MEDICATION-ASSISTED TREATMENT (MAT)-RELATED HEALTHCARE RESOURCE UTILIZATION AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MAT RECEIVED

    Nov 1, 2019, 00:00

  • PNS402 PERCEIVED BARRIERS TO ENSURING THE EFFECTIVE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS

    Nov 1, 2019, 00:00

  • PRO49 ANNUAL COST OF TREATMENT OF SPINAL MUSCULAR ATROPHU PATIENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PCN126 REAL-WORLD TREATMENT SEQUENCING OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): WHAT ARE THE HEALTH ECONOMIC IMPLICATIONS?

    Nov 1, 2019, 00:00

  • PNS181 SUBMISSIONS TO A NATIONAL HTA AGENCY IN IRELAND: DRUGS WITH DESIGNATED ORPHAN STATUS

    Nov 1, 2019, 00:00

  • PIH42 HEALTHCARE RESOURCE USE FOR THE MANAGEMENT OF POSTPARTUM HAEMORRHAGE IN FRANCE, ITALY, THE NETHERLANDS, AND THE UK

    Nov 1, 2019, 00:00

  • Cancer - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMU65 PRICE ANALYSIS OF NEW MEDICINAL PRODUCTS REIMBURSED IN ITALY AND GERMANY

    Nov 1, 2019, 00:00

  • NO Specific Disease - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PMD54 MEDICAL CAPITAL EQUIPMENT TENDER ANALYTICS: META ANALYSIS ON WIN/LOSS STUDIES

    Nov 1, 2019, 00:00

  • PNS334 SCIENTIFIC MISCONDUCT AND SYSTEMATIC LITERATURE REVIEWS (SLRS): THE IMPACT OF FRAUDULENT CLINICAL STUDIES ON EVIDENCE-BASED MEDICINE

    Nov 1, 2019, 00:00

  • PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PMS27 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE HIP AND THIGH IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN179 TREOSULFAN-BASED CONDITIONING VS BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML OR MDS — A UK COST-UTILITY ANALYSIS

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS56 EVALUATION OF THE IMPACT OF ALTERNATIVE DRUG PRICING STRATEGIES USED ON THE BUDGET IMPACT AND COST-EFFECTIVENESS FOR PRODUCTS WITH MULTIPLE INDICATIONS

    Nov 1, 2019, 00:00

  • PRO140 KNOWLEDGE, USE AND DESIDERATA ABOUT INFORMATION AND COMMUNICATION TECHNOLOGIES SYSTEMS FOR SYSTEMIC LUPUS ERYTHEMATOSUS. PRELIMINARY RESULTS FROM THE INTEGRATE PILOT PROJECT.

    Nov 1, 2019, 00:00

  • PCN230 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PIN110 HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN ADULTS 65 YEARS AND OLDER IN 5 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN212 ECONOMIC EVALUATION OF TOPOTECAN IN COMPARISON WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OVARIAN CANCER IN IRAN

    Nov 1, 2019, 00:00

  • PDB122 REAL-WORLD INSULIN THERAPY IN GERMAN TYPE 2 DIABETES MELLITUS PATIENTS: PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND INSULIN DOSAGE

    Nov 1, 2019, 00:00

  • Reimbursement Access Policy Research

    Nov 1, 2019, 00:00

  • PSY38 MARGINAL STRUCTURAL MODEL FOR STUDYING THE CAUSAL EFFECT BETWEEN VASO-OCCLUSIVE CRISES AND OCCURENCE OF DEATH OR COMPLICATIONS IN THE SICKLE-CELL DISEASE PATIENTS

    Nov 1, 2019, 00:00

  • PNS406 BURDEN OF POST-TRANSPLANT OUTCOMES AFTER LIVER TRANSPLANTATION IN SOUTH KOREA: KOREAN ORGAN TRANSPLANTATION REGISTRY (KOTRY) ANALYSIS STUDY

    Nov 1, 2019, 00:00

  • PIN46 CONTRASTING AVAILABLE THERAPY FOR PATIENTS WITH LIMITED OPTIONS DUE TO EXTREMELY DRUG-RESISTANCE BACTERIA WITH A NOVEL OPTION FOR COMPLICATED NOSOCOMIAL INFECTIONS

    Nov 1, 2019, 00:00

  • PNS64 DOES IT WORTH TO INVEST ON INTRAOPERATIVE HYPOTHERMIA PREVENTION? - HYBRID EVIDENCES FROM META-ANALYSES AND COST-BENEFIT ANALYSIS

    Nov 1, 2019, 00:00

  • PCN292 CURRENT AND FUTURE EU5 PAYER LANDSCAPE FOR ONCOLOGY SOMATIC MUTATION PANELS

    Nov 1, 2019, 00:00

  • PCN261 ESTIMATING THE NUMBER OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE ACROSS EUROPE

    Nov 1, 2019, 00:00

  • PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS196 EXPERIENCES WITH SUPPLEMENTARY HEALTH INSURANCE POLICIES IN HUNGARY AND OTHER EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN270 AVAILABILITY OF EARLY PREVENTION AND TARGETED THERAPY FOR BRCA-ASSOSIATED PATIENTS WITH BREAST AND/OR OVARIAN CANCER

    Nov 1, 2019, 00:00

  • Health Utilities and Costs for Motor Neurone Disease

    Nov 1, 2019, 00:00

  • PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PCN396 CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-TS): ARE ONGOING CLINICAL TRIALS DESIGNED TO MEET EVIDENCE NEEDS OF KEY EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES (HTABS)?

    Nov 1, 2019, 00:00

  • PCN130 COST OF ILLNESS ANALYSIS: DRUG THERAPY OF PATIENTS WITH MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS IN MOSCOW

    Nov 1, 2019, 00:00

  • PMU8 IS PREFERENCE OF ELICITATION TECHNIQUE BASED ON THE DISEASE AREA BEING STUDIED?

    Nov 1, 2019, 00:00

  • MT3 OUTCOMES AND HOSPITAL UTILIZATION OF SLEEP APNEA PATIENTS TREATED WITH POSITIVE AIRWAY PRESSURE DURING AND AFTER ONSET OF HEART FAILURE

    Nov 1, 2019, 00:00

  • PNS351 ROLE OF MARKET ACCESS (MA), AND HEALTH ECONOMIC AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS.

    Nov 1, 2019, 00:00

  • Surgery - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PIT6 MEASURING PROMS OF REHABILITATION WITH COMPUTER ADAPTIVE TESTING (CAT) AFTER AN OPERATIVE INTERVENTION OF AN EXTREMITY FRACTURE

    Nov 1, 2019, 00:00

  • Surgery - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PNS322 REVIEW OF METHODOLOGICAL APPROACHES TO ANALYSE LONGITUDINAL UTILITY DATA

    Nov 1, 2019, 00:00

  • PCN310 "FREE” VS "CONTROLLED” PRICING SYSTEM: A EUROPEAN ASSESSMENT OF THE DISPARITIES IN ACCESS TO ONCOLOGY DRUGS

    Nov 1, 2019, 00:00

  • PNS353 PRICING AND MARKET ACCESS LAUNCH EXCELLENCE: WHAT ARE THE KEY CHALLENGES FACING COMPANIES TODAY?

    Nov 1, 2019, 00:00

  • PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.

    Nov 1, 2019, 00:00

  • PCV64 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF CARDIAC ARREST IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • ND2 THE IMPACT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS ON WORK-RELATED OUTCOMES: A MIXED METHODS APPROACH

    Nov 1, 2019, 00:00

  • PCN6 EVALUATING THE QUALITY AND RISK OF BIAS IN OVERALL SURVIVAL OUTCOMES FROM NON-RANDOMISED CAR T-CELL THERAPY PIVOTAL TRIALS

    Nov 1, 2019, 00:00

  • PND82 A DELPHI PANEL ON TREATMENT OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN447 NEW METHODOLOGY IN PARAMETRIC NETWORK META-ANALYSIS: NON-MIXTURE CURE MODELS

    Nov 1, 2019, 00:00

  • PBI15 ECONOMIC BURDEN OF SICKLE CELL DISEASE: A TARGETED GLOBAL LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN441 NEW METHODOLOGY IN NETWORK META-ANALYSIS USING MIXTURE CURE MODELS

    Nov 1, 2019, 00:00

  • PNS129 NET PRICES OF GENERICS IN GREECE DUE TO PAYBACKS: UPDATING THE FACTS

    Nov 1, 2019, 00:00

  • PND28 THE ECONOMIC BURDEN OF MULTIPLE SCLEROSIS DEVELOPMENT OVER TIME: AN ANALYSIS FROM THE MULTIPLE SCLEROSIS CENTERS PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRS44 CHARACTERISTICS OF MEDICARE ADVANTAGE BENEFICIARIES INITIATING LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA) USING DRY POWDER OR SOFT MIST INHALERS

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?

    Nov 1, 2019, 00:00

  • PCN529 BURDEN OF ILLNESS IN NEW OSTOMATES: AN ANALYSIS BASED ON GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PIN67 BUDGET IMPACT ANALYSIS OF THE IMPLEMENTATION OF A PRESURGICAL WARMING PROTOCOL TO EFFECTIVELY MANAGE SURGICAL PATIENT NORMOTHERMIA

    Nov 1, 2019, 00:00

  • PMS8 RATE OF FRACTURES LEADING TO HOSPITALISATION AND HEALTHCARE BURDEN IN UNTREATED OSTEOPOROSIS ELDERLY PATIENTS IN GERMANY: AN INGEF HEALTHCARE INSURANCE DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PNS80 COST-EFFECTIVENESS ANALYSES OF PERSONALISATION/HOME CARE FOR OLDER PEOPLE COMPARED TO NURSING HOME CARE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN359 VALUE ASSESSMENT OF HTA DECISIONS FOR PD-1/PD-L1 INHIBITORS IN ONCOLOGY: A NICE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB64 COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PAM13 IMPACT ON CARERS OF ADULT PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PNS36 A CONCEPTUAL PAPER ON THE USE OF PATIENT SUPPORT PROGRAMS IN PROVIDING BETTER ACCESS TO MEDICAL CARE IN EGYPT

    Nov 1, 2019, 00:00

  • PCN428 SCALABLE PREDICTION OF CANCER PATIENT CLINICAL EVENTS IN REAL WORLD CLINICAL SETTINGS

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PBI42 ANALYSIS OF GENE AND CELL THERAPIES POLICIES IN EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PBI21 TREATMENT COSTS OF MATRIX-ASSOCIATED AUTOLOGOUS CHONDROCYTES IMPLANTATION COMPARED TO MICROFRACTURE — RESULTS OF A MATCHED-PAIR CLAIMS DATA ANALYSIS ON TREATMENT OF CARTILAGE KNEE DEFECTS IN GERMANY

    Nov 1, 2019, 00:00

  • PMU80 DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN

    Nov 1, 2019, 00:00

  • PNS376 EQUIVALENCE OF ONLINE METHODS TO ASSESS CONTENT VALIDITY

    Nov 1, 2019, 00:00

  • PMU55 HURDLES TO REGULATORY AND ACCESS (PRICING AND REIMBURSEMENT) OF 3D-PRINTED TUMOR ASSAYS FOR PERSONALIZED MEDICINE IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PMU104 NAVIGATING DIVERGENCE: ACCOMMODATING THE MULTITUDE OF NEW PAYER BODIES IN EMERGING MARKETS

    Nov 1, 2019, 00:00

  • PCV63 WHAT'S THE COST OF HOSPITALISATIONS DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE UNITED STATES?

    Nov 1, 2019, 00:00

  • PCV15 POTENTIAL IMPACT OF PROLONGED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR IN 'REAL WORLD' STABLE PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION VERSUS RANDOMIZED CONTROLLED TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PSS19 HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND ASSOCIATED FINANCIAL BURDEN AMONG ADULTS WITH PSORIASIS

    Nov 1, 2019, 00:00

  • PCN30 ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

    Nov 1, 2019, 00:00

  • PDB108 THE UNMET MEDICAL NEEDS IN CURRENT ANTIDIABETIC INJECTABLE THERAPY (AIT) IN CHINA: FROM THE PERSPECTIVE OF HEALTHCARE PROVIDERS (HCPS)

    Nov 1, 2019, 00:00

  • PCN527 US HEALTHCARE DATABASES FOR HEALTH ECONOMIC MODELING IN PRECISION MEDICINE: AN ONCOLOGY-BASED COMPARATIVE LANDSCAPE ASSESSMENT

    Nov 1, 2019, 00:00

  • PRO42 THE CLINICAL, HUMANISTIC AND ECONOMIC BURDEN OF BRONCHIOLITIS OBLITERANS SYNDROME IN EUROPE

    Nov 1, 2019, 00:00

  • AI2 GEO-SPATIAL RISK ASSESSMENT OF ASTHMA HEALTH RESOURCE USE AT THE MUNICIPAL LEVEL IN THE GREATER HELSINKI METROPOLITAN AREA OF FINLAND

    Nov 1, 2019, 00:00

  • PIN34 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING CHILDREN AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA

    Nov 1, 2019, 00:00

  • PMU72 ATTRIBUTES OF DISSATISFACTION OF HEALTH INSURANCE COVERAGE IN PATIENTS VISITED PUBLIC AND PRIVATE DENTAL HEALTHCARE CENTERS

    Nov 1, 2019, 00:00

  • PDB23 SWITCHING TO INSULIN DEGLUDEC IS A COST-SAVING THERAPY FOR PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES IN THE SWEDISH SETTING BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • Personalized Statistical Research

    Nov 1, 2019, 00:00

  • PMS41 PROJECTION OF THE PREVALENCE OF RHEUMATIC DISEASES IN PORTUGAL THROUGH THE FIRST HALF OF THE 21ST CENTURY

    Nov 1, 2019, 00:00

  • PMS64 ASSESSING THE QUALITY OF BIOLOGIC SWITCH DECISIONS IN PSORIATIC ARTHRITIS: VALIDATION OF PASQAL - AN OUTCOMES MEASUREMENT TOOL

    Nov 1, 2019, 00:00

  • PMS70 PSYCHOLOGICAL SYMPTOMS AND TOTAL KNEE REPLACEMENT.

    Nov 1, 2019, 00:00

  • PBI49 THE EXPEDITED REGULATORY PROGRAMS FOR REGENERATIVE MEDICINES IN US, EU AND JAPAN

    Nov 1, 2019, 00:00

  • PIN116 THE BURDEN OF INFLUENZA POSITIVE INPATIENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PNS277 THE ROLE OF EARLY VALUE FRAMEWORK IN A SUCCESSFUL REIMBURSEMENT JOURNEY

    Nov 1, 2019, 00:00

  • PNS315 ON THE USE OF DISCOUNT RATES IN ONE-WAY SENSITIVITY ANALYSIS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PBI68 ADDED BENEFIT ASSESSMENT OF ATMPS IN GERMANY: DOES THE DATA BASIS MEET HTA REQUIREMENTS?

    Nov 1, 2019, 00:00

  • PND38 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN172 COST-EFFECTIVENESS OF CRC FRENCH SCREENING PROGRAMME FOR AVERAGE RISK INDIVIDUALS

    Nov 1, 2019, 00:00

  • PCN210 RESOURCE UTILIZATION AND COST FOR WOMEN WITH ADVANCED HR+/HER2- BREAST CANCER IN COLOMBIAN HEALTH CARE SETTINGS

    Nov 1, 2019, 00:00

  • PIH44 SURGICAL TREATMENT OF PATIENTS NEWLY DIAGNOSED WITH UTERINE FIBROIDS: A CLAIMS-BASED DATA ANALYSIS

    Nov 1, 2019, 00:00

  • PCV80 EVALUATION OF THE QUALITY OF LIFE OF PATIENTS WITH CARDIOVASCULAR DISEASES IN NUR-SULTAN, KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PNS222 NEEDS AND RISKS ASSESSMENT IN CREATION OF HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PDB21 PREDICTING HEALTHCARE COSTS OF DIABETES USING MACHINE LEARNING MODELS

    Nov 1, 2019, 00:00

  • PMU144 DISEASE STATE ADAPTATION AND ESTIMATES OF QUALITY-OF-LIFE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS327 DO FLEXIBLE SURVIVAL MODELS PROVIDE BETTER EXTRAPOLATIONS THAN STANDARD SURVIVAL MODELS? A SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PCV136 PATIENT PREFERENCES FOR MITRAL VALVE PROCEDURE-ASSOCIATED BENEFITS REVEAL GREATER RISK TOLERANCE AS HEART FAILURE SYMPTOMS WORSEN

    Nov 1, 2019, 00:00

  • PMD45 A COMPANION APP TO SUPPORT PATIENTS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM A USABILITY STUDY

    Nov 1, 2019, 00:00

  • PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT

    Nov 1, 2019, 00:00

  • PAM14 ASSESSING THE NUTRITIONAL STATUS OF THE ELDERLY USING STANDARD STATUS SCALES

    Nov 1, 2019, 00:00

  • PDB73 RELATIONSHIP BETWEEN METABOLIC SYNDROME RISK LEVEL, BODY COMPOSITION AND LIPID PROFILE AMONG ADULTS IN MONGOLIA

    Nov 1, 2019, 00:00

  • PSU13 COST UTILITY ANALYSIS OF ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY VERSUS OPEN RADICAL NEPHRECTOMY IN KOREAN PATIENTS WITH RENAL CANCER

    Nov 1, 2019, 00:00

  • PNS45 ADDING NOISE TO MARKOV COHORT MODELS

    Nov 1, 2019, 00:00

  • PRO50 THE ECONOMIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • ON4 THE ECONOMIC BURDEN OF RENAL CELL CARCINOMA (RCC) IN CANADA USING REAL-WORLD EVIDENCE; A SOCIETAL PERSPECTIVE.

    Nov 1, 2019, 00:00

  • PMU113 IS THERE AN ASSOCIATION BETWEEN ERG AND NICE REIMBURSEMENT RECOMMENDATIONS?

    Nov 1, 2019, 00:00

  • PNS42 TO WHAT EXTENT DOES SEEKING CLINICAL EXPERT OPINION FOR MODEL INPUTS REDUCE THE COST OF UNCERTAINTY? A CONCEPTUAL APPROACH USING EXPECTED VALUE OF PERFECT PARAMETER INFORMATION (EVPPI)

    Nov 1, 2019, 00:00

  • PMU132 PUBLICATION PATTERNS IN PATIENT-REPORTED OUTCOMES IN ORIGINAL RESEARCH ARTICLES ABOUT DIABETES AND INFLAMMATORY BOWEL DISEASE

    Nov 1, 2019, 00:00

  • PSY5 COST-UTILITY OF TOFACITINIB FOR THE TREATMENT OF SEVERE TO MODERATE RHEUMATOID ARTHRITIS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN399 ASSESSMENT OF SURROGACY OUTCOMES FOR OVERALL SURVIVAL IN ONCOLOGY BASED ON NICE APPRAISALS AND POST-APPRAISAL EVIDENCE

    Nov 1, 2019, 00:00

  • PCV129 SELF-ASSESSED FUNCTIONAL INSTRUMENT IN HEART FAILURE: CORRELATION WITH PATIENT REPORTED SYMPTOMS

    Nov 1, 2019, 00:00

  • PDB42 COST-EFFECTIVENESS ANALYSIS FOR HBA1C TEST INTERVALS IN PATIENTS ON TREATMENT FOR STABLE TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS345 BUSINESS MODEL INNOVATION OF INTERNET HOSPITALS IN CHINA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCV29 COST-EFFECTIVENESS OF CORONARY AND PERIPHERAL ARTERY DISEASE TREATMENTS

    Nov 1, 2019, 00:00

  • PCN435 IMPROVED ESTIMATES OF EXTRAPOLATED MEAN SURVIVAL TIMES USING FINITE MIXTURE MODELS: REDUCING UNCERTAINTY IN COST EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00

  • PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PCV65 FEE FOR SERVICE VERSUS LUMP SUM PAYMENT: COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN GERMANY - PRIVATE INSURANCE VERSUS STATUTORY SICK FUNDS

    Nov 1, 2019, 00:00

  • PRS68 A RETROSPECTIVE DATABASE STUDY OF A CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT COHORT TO EVALUATE THE PATIENT CHARACTERISTICS AND ECONOMIC BURDEN OF ILLNESS IN ENGLAND

    Nov 1, 2019, 00:00

  • PIH65 IMPACT ON CARERS OF PAEDIATRIC PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE

    Nov 1, 2019, 00:00

  • PMU51 BARRIERS AGAINST PROGRAMS FOR THE PREVENTION OF IODINE DEFICIENCY DISORDERS IN EUROPE: A DELPHI STUDY

    Nov 1, 2019, 00:00

  • PMD30 MEDICAL DEVICES MANAGED ENTRY AGREEMENTS IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019)

    Nov 1, 2019, 00:00

  • PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME

    Nov 1, 2019, 00:00

  • PNS298 PER-MEMBER PER-MONTH (PMPM) EXPENDITURE VALUE IN ONCOLOGY: A QUICK LITERATURE REVIEW AND OPINION

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS414 COMPARISON OF THREE LARGE REAL-WORLD DATABASES FROM THREE DIFFERENT COUNTRIES AND IMPLICATIONS FOR THEIR USE FOR RETROSPECTIVE STUDIES

    Nov 1, 2019, 00:00

  • PSU14 HEALTHCARE BURDEN OF SURGICAL SITE INFECTIONS FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY

    Nov 1, 2019, 00:00

  • PRO109 A COMPARATIVE REVIEW OF NICE AND SMC DECISION-MAKING FOR ULTRA-ORPHAN MEDICINES

    Nov 1, 2019, 00:00

  • PMU54 A 10-YEAR REVIEW (2009-2018) OF MARKET ACCESS OF PHARMACEUTICALS IN THE EU5 AND US

    Nov 1, 2019, 00:00

  • PNS234 INTERNATIONAL HTA FRAMEWORKS AS ROADMAP TO REVISIT PHARMA ORGANISATION AND OPERATIONS

    Nov 1, 2019, 00:00

  • PUK16 COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER

    Nov 1, 2019, 00:00

  • PRO22 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ECONOMIC BURDEN OF DUCHENNE MUSCULAR DYSTROPHY (DMD): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN44 COMPARATIVE EFFECTIVENESS OF EARLY VS. LATE USE OF SORAFENIB IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN

    Nov 1, 2019, 00:00

  • PIH62 INVESTIGATING THE RESPONSIVENESS TO CHANGE OF THE HIV TREATMENT SATISFACTION QUESTIONNAIRE CHANGE VERSION (HIVTSQC) IN OVERCOMING CEILING EFFECTS IN THE HIV TREATMENT SATISFACTION QUESTIONNAIRE STATUS VERSION (HIVTSQS)

    Nov 1, 2019, 00:00

  • PIN73 THE POTENTIAL COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INACTIVATED INFLUENZA VACCINE FOR THE PORTUGUESE ELDERLY POPULATION

    Nov 1, 2019, 00:00

  • PCN381 KEY FACTORS FOR THE CONSIDERATION OF QUALITY OF LIFE DATA IN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMH19 HEALTH CARE COSTS RELATED TO SCHIZOPHRENIA IN PATIENTS INITIATING ARIPIPRAZOLE LONG-ACTING INJECTABLE (LAI): RESULTS FROM THE DOMINO STUDY

    Nov 1, 2019, 00:00

  • PGI59 INCREASED AVAILABILITY OF REIMBURSED INTERFERON-FREE TREATMENTS FOR HCV IN POLAND AND ITS COST

    Nov 1, 2019, 00:00

  • PIH67 THE CHANGES OF COST FOR PREECLAMPSIA PREGNANCY AFTER THE ANGIOGENIC FACTORS (SFLT-1 AND PLGF) TESTS. PRELIMINARY DATA OF AN ECONOMIC MODEL BASED ON LOCAL RWD.

    Nov 1, 2019, 00:00

  • PCN169 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE

    Nov 1, 2019, 00:00

  • PIH31 BURDEN OF SHINGLES IN THE OVER 80'S IN THE UK

    Nov 1, 2019, 00:00

  • PBI66 ARE HTA AGENCIES BUYING INTO THE CAR-T HYPE?

    Nov 1, 2019, 00:00

  • PNS337 IMPROVING ON CYCLE CORRECTIONS FOR TIME-HOMOGENEOUS MARKOV MODELS

    Nov 1, 2019, 00:00

  • PND30 THE SOCIETAL IMPACT OF ERENUMAB IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE IN GERMANY: A MACROECONOMIC OPEN-COHORT APPROACH

    Nov 1, 2019, 00:00

  • PMS28 HEALTHCARE SERVICE UTILISATION BY PATIENTS WITH CHRONIC LOW BACK PAIN - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH

    Nov 1, 2019, 00:00

  • PCN433 DISCRETE TIME RESTRICTED CUBIC SPLINE MODELS FOR NETWORK META-ANALYSIS OF TIME-TO-EVENT OUTCOMES

    Nov 1, 2019, 00:00

  • PCN77 COST-UTILITY, COST-EFFECTIVENESS, AND BUDGET IMPACT OF INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY FOR BREAST CANCER SURVIVORS WITH TREATMENT-INDUCED MENOPAUSAL SYMPTOMS

    Nov 1, 2019, 00:00

  • PRO75 PATIENT ACCESS TO ORPHAN MEDICINES IN TURKEY

    Nov 1, 2019, 00:00

  • PNS363 VALUATION OF EQ-5D-Y HEALTH INDEX UISNG DISCRETE CHOICE EXPERIMENT (DCE) IN HONG KONG ADOLESCENT POPULATION: PILOT FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PMU151 ECONOMIC BURDEN OF BIOSIMILAR DELIVERY IN FRANCE: REAL WORLD ANALYSIS FROM THE PERMANENT SAMPLE OF NATIONAL HEALTH INSURANCE BENEFICIARIES, BETWEEN 2007 TO 2017

    Nov 1, 2019, 00:00

  • PNS382 ACCURACY OF PRO DATA SIGNIFICANTLY IMPROVES WITH SUBJECT TRAINING IN MIGRAINE CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PMD26 THE ECONOMIC EVALUATION OF THE SFLT-1/PIGF RATIO IN THE PREDICTION OF PRE-ECLAMPSIA

    Nov 1, 2019, 00:00

  • PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM)

    Nov 1, 2019, 00:00

  • PDB11 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): TOTAL COSTS

    Nov 1, 2019, 00:00

  • PNS157 WHY EMERGENCY ACCESS TO DRUG TECHNOLOGES IN POLAND DOES NOT WORK?

    Nov 1, 2019, 00:00

  • PNS227 THE NOT-NICE ACCESS PATHWAY: NHS ENGLAND SPECIALISED COMMISSIONING

    Nov 1, 2019, 00:00

  • Neurological Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PND37 10-YEAR COST-EFFECTIVENESS ANALYSES OF RESPONSE-BASED USE OF FREMANEZUMAB AS PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PBI41 CHALLENGES AND OPPORTUNITIES FOR THE REIMBURSEMENT OF GENE THERAPIES - STAKEHOLDER INSIGHTS FROM GERMANY, SWEDEN AND THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PND116 QUALITATIVE CONCEPT ELICITATION INTERVIEWS TO UNDERSTAND THE PATIENT EXPERIENCE OF GLUCOCEREBROSIDASE-PARKINSON'S DISEASE (GBA-PD)

    Nov 1, 2019, 00:00

  • PND129 BAD WEATHER CAUSES MIGRAINE? ASSOCIATION BETWEEN METEOROLOGICAL VARIABLES, HEADACHES AND MIGRAINE USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN217 COST-EFFECTIVENESS OF LENVATINIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE UK

    Nov 1, 2019, 00:00

  • PRO150 A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUATIONS IN HAEMOPHILIA

    Nov 1, 2019, 00:00

  • PNS356 PAYERS RELATED ISSUES ARISING FROM THE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS AT PRE-LAUNCH

    Nov 1, 2019, 00:00

  • PNS411 ASSESSMENT OF THE ACTIVITY OF PHARMACISTS IN ENSURING THE SAFE USE OF MEDICINES IN UKRAINE

    Nov 1, 2019, 00:00

  • PDG48 AN ANALYSIS OF THE DANISH MODEL FOR ANALOGUE COMPETITION OF HOSPITAL MEDICINE BASED ON THE THERAPEUTIC AREA, HEPATITIS C

    Nov 1, 2019, 00:00

  • PMH36 ST. JOHN'S WORT THERAPY IS ASSOCIATED WITH A REDUCED INCIDENCE OF DEMENTIA IN PATIENTS TREATED IN GENERAL PRACTICES

    Nov 1, 2019, 00:00

  • PND71 EPIDEMIOLOGY OF ATTENTION DEFICIT HYPERACTIVITY DISORDERS IN SPAIN BASED ON REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • Mental Health - Medical Technologies

    Nov 1, 2019, 00:00

  • PDG83 PHARMACEUTICAL PRICING: LAUNCH STRATEGY RULES? ANALYSIS OF GERMAN DATA

    Nov 1, 2019, 00:00

  • PCN12 USING CLINICAL DATA STANDARDS TO FACILITATE COMPARISONS OF ACUTE MYELOID LEUKEMIA TREATMENT PATTERNS AND OUTCOMES IN REAL WORLD CLINICAL CARE AND POOLED CLINICAL TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PCV143 SACUBITRIL/VALSARTAN PRESCRIPTION PATTERNS AND TITRATION IN A REAL-WORLD SETTING IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PMD9 INTRODUCING BUDGET IMPACT ANALYSIS COMPARING REUSABLE TO SINGLE-USE BRONCHOSCOPES WITHIN A LARGE UK UNIVERSITY HOSPITAL

    Nov 1, 2019, 00:00

  • PMD16 HEALTH ECONOMIC VALUE OF BLOOD IN IVORY COAST: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PDG68 USE OF ANTICANCER DRUGS IN IVORY COAST FROM 2017 TO 2018

    Nov 1, 2019, 00:00

  • PCV146 CHARACTERIZATION OF PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Nov 1, 2019, 00:00

  • PRS20 INFLUENCE OF COPD SEVERITY AND ITS COMORBIDITIES ON DIRECT AND INDIRECT COSTS: RESULTS FROM THE LQ-DMP STUDY

    Nov 1, 2019, 00:00

  • CV4 HOSPITALIZED WITH STROKE AT THE WEEKEND: ARE THERE HIGHER RISK OF EARLY DEATH AND HIGHER COSTS?

    Nov 1, 2019, 00:00

  • PNS136 MEDICAL DEVICES PRICE SETTING IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019)

    Nov 1, 2019, 00:00

  • PSU2 INDIRECT TREATMENT COMPARISON OF MINIMALLY INVASIVE GLAUCOMA SURGERGIES ON TOP OF PHACOEMULSIFICATION IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA

    Nov 1, 2019, 00:00

  • PRO53 WHAT IS THE RELATIONSHIP BETWEEN PRICE AND PREVALENCE IN NON-ONCOLOGY RARE DISEASE?

    Nov 1, 2019, 00:00

  • PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN

    Nov 1, 2019, 00:00

  • CE3 COMPARATIVE EFFECTIVENESS AMONG SINGLE AGENT CHEMOTHERAPEUTICS IN THE TREATMENT OF TNBC USING TIME TO NEXT TREATMENT AS A SURROGATE FOR EFFICACY

    Nov 1, 2019, 00:00

  • Cancer - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PIN151 PATIENTS TREATED FOR HEPATITIS C: AN OBSERVATIONAL STUDY WITH THE FRENCH ADMINISTRATIVE HEALTH CARE DATABASE (SNDS)

    Nov 1, 2019, 00:00

  • PCN152 COST-UTILITY AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE FOR EVALUATION OF ENTRECTINIB VERSUS STANDARD OF CARE IN ROS1+ NSCLC PATIENTS

    Nov 1, 2019, 00:00

  • PIH34 THE ASSOCIATION BETWEEN ANTICHOLINERGIC MEDICINE AND COGNITION DECLINE IN OLDER ADULTS: A SYSTEMIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2019, 00:00

  • PCN466 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CLINICAL PRACTICE FOR IMMUNE-CHECKPOINT INHIBITORS (ICI)-TREATED PATIENTS: WHAT ARE PATIENTS' EXPERIENCES AND EXPECTATIONS? RESULTS FROM AN ONLINE PATIENT COMMUNITY RESEARCH

    Nov 1, 2019, 00:00

  • PMS32 COST MINIMIZATION ANALYSIS OF ZENTIUS FOR THE TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCY IN TURKEY

    Nov 1, 2019, 00:00

  • PSY8 ECONOMIC EVALUATION OF GUSELKUMAB AND OTHER IL-INHIBITORS FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ITALY

    Nov 1, 2019, 00:00

  • PUK20 ECONOMIC EVALUATION OF CILOSTAZOL IN COMPARISON WITH PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION IN IRAN

    Nov 1, 2019, 00:00

  • PRO154 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE BRIEF PAIN INVENTORY (BPI-SF) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00

  • PIH26 JUVENILE IDIOPATHIC ARTHRITIS IS ASSOCIATED WITH CONSIDERABLE FINANCIAL BURDEN TO SOCIETY: RESULTS OF A DUTCH COST ANALYSIS

    Nov 1, 2019, 00:00

  • PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING

    Nov 1, 2019, 00:00

  • PCN307 IMPROVING PATIENT ACCESS TO PD-(L)1 THERAPIES IN CHINA: POLICY IMPLICATIONS FROM PREVIOUS NRDL NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PCN84 COST OF ILLNESS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITALY

    Nov 1, 2019, 00:00

  • Multiple Diseases - Medical Technologies

    Nov 1, 2019, 00:00

  • PIH35 RATES OF DELIVERY WITH COMPLICATING CONDITIONS AND POSTPARTUM COMPLICATION RATES FOLLOWING DELIVERY SURGE AMONG U.S. MOTHERS

    Nov 1, 2019, 00:00

  • PMD43 EFFICACY AND SAFETY OF MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE: AN UMBRELLA SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PSS23 DISEASE BURDEN IN PATIENTS WITH MILD PSORIASIS: GROUP CONCEPT MAPPING

    Nov 1, 2019, 00:00

  • PNS62 HEALTH ECONOMIC VALUE OF BLOOD IN GHANA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PGI42 THE NEW WAVE OF ULCERATIVE COLITIS BIOLOGICS: CONSTRAINED BY THE COST-CONSCIOUS EUROPEAN MARKETS OR CHALLENGING THE TREATMENT PARADIGM?

    Nov 1, 2019, 00:00

  • PND91 APPLICATION OF BIG DATA IN RARE DISEASE MANAGEMENT: TREATMENT COST OF THERAPEUTIC PLASMA EXCHANGE VERSUS IMMUNOGLOBULINS IN AN INPATIENT SETTING

    Nov 1, 2019, 00:00

  • PNS26 USING SURROGATES FOR PREDICTION OVERALL SURVIVAL IN ONCOLOGY: CONSIDERATIONS FOR NEW TREATMENTS AND EARLIER STAGES OF CANCER

    Nov 1, 2019, 00:00

  • PMS29 HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PMD23 BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE

    Nov 1, 2019, 00:00

  • PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • Cancer - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PMU77 OPIOID USE PATTERNS AND HEALTHCARE USE AMONG INDIVIDUALS WITH COMORBID CHRONIC NON-CANCER PAIN AND OBSTRUCTIVE SLEEP APNEA

    Nov 1, 2019, 00:00

  • PNS37 SHOULD WE CONSTANTLY BE COUNTING WITH CONSTANT DISCOUNTING?

    Nov 1, 2019, 00:00

  • PRO137 PATIENT CHARACTERISTICS ASSOCIATED WITH GREATER HIDRADENITIS SUPPURATIVA SEVERITY AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PBI47 PAYER AND PRESCRIBER PERSPECTIVES ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES IN DIFFUSE LARGE B-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PCN515 A SURVEY OF CLINICAL PRACTICE FOR THE FRONTLINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • Individual's Health - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PND95 PRODUCTIVITY LOSS COST IN MIGRAINE USING TWO DIFFERENT QUESTIONNAIRES: FINDINGS FROM THE BECOME STUDY FOR PORTUGAL

    Nov 1, 2019, 00:00

  • Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward [Editor's Choice]

    Nov 1, 2019, 00:00

  • PND83 ACCESS TO INTRAVENOUS TISSUE-LIKE PLASMINOGEN ACTIVATOR (IV TPA) THERAPY AND MECHANICAL THROMBECTOMY (MT) FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN HUNGARY

    Nov 1, 2019, 00:00

  • Surgery - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PNS127 THE DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTOR (CAR-T) CELL THERAPY IN CHINA

    Nov 1, 2019, 00:00

  • PCN303 ITALIAN NATIONAL HEALTH SERVICE REIMBURSEMENT POLICY FOR ONCOLOGY DRUGS AFTER CONDITIONAL MARKET AUTHORIZATION GRANTED BY THE EUROPEAN MEDICINE AGENCY: A RETROSPECTIVE ANALYSIS

    Nov 1, 2019, 00:00

  • Surgery - Organizational Practices

    Nov 1, 2019, 00:00

  • PCN514 REAL WORLD TREATMENT PATHWAYS OF DIFFUSE LARGE B-CELL LYMPHOMA IN GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PRS36 EPIDEMIOLOGICAL AND CLINICAL FEATURES OF HMPV AND RSV INFECTIONS AMONG CHILDREN HOSPITALIZED FROM ACUTE RESPIRATORY INFECTIONS IN MACAO: A RETROSPECTIVE STUDY FROM 2014 TO 2017

    Nov 1, 2019, 00:00

  • Neurological Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PIN75 WHAT WE KNOW NOW: REVISITING THE COST-EFFECTIVENESS OF CHICKENPOX VACCINATION USING AN AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • PDG62 THE CONTINUUM OF INTERNATIONAL REFERENCE PRICING USE IN LATIN AMERICA: A QUALITATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PGI14 PHARMACOECONOMIC ASPECTS OF TREATMENT OF ACUTE PANCREATIS IN CENTRAL PART OF SERBIA - COST OF ILLNESS STUDY BASED ON DATA FROM TERTIARY REFERRAL HOSPITAL

    Nov 1, 2019, 00:00

  • PSU19 ROBOTIC ASSISTED GASTRECTOMY COMPARED WITH OPEN RESECTION: A CASE-MATCHED STUDY OF CLINICAL OUTCOMES AND COST-EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PNS75 PROPER INCORPORATION OF ADVERSE EVENTS FROM MEDICAL TREATMENTS (AEMT) IN HEALTH TECHOLOGY ASSESSMENTS (HTA)

    Nov 1, 2019, 00:00

  • PNS247 THE IMPLICATIONS OF EUROPEAN JOINT CLINICAL ASSESSMENT FOR MEMBER STATE PRICING MARKET ACCESS

    Nov 1, 2019, 00:00

  • PDB54 ECONOMIC EVALUATION OF A NEW POLYGENIC RISK SCORE TO PREVENT NEPHROPATHIES IN TYPE-2 DIABETIC PATIENTS

    Nov 1, 2019, 00:00

  • PCV38 HEALTH OUTCOMES PROJECTIONS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN A REAL-WORLD POPULATION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PRO149 PATIENT ENGAGEMENT IN RESEARCH: THE EURORDIS PATIENT-LED COMMUNITY ADVISORY BOARDS (CABS)

    Nov 1, 2019, 00:00

  • PNS101 ASSOCIATION BETWEEN RISK FACTORS AND SAFE DRUG DISPOSAL IN COMMUNITY: A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PIN28 COST EFFECTIVENESS ANALYSIS OF BACILLUS CALMETTE-GUÉRIN VACCINATION IN INDONESIA

    Nov 1, 2019, 00:00

  • PMS31 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-NAIVE PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PRO88 PAYER AND PHYSICIAN PERSPECTIVES OF CURRENT AND EMERGING SPINAL MUSCULAR ATROPHY TREATMENTS IN THE EU5

    Nov 1, 2019, 00:00

  • PIN129 ANALYSIS OF THE RELATIONSHIP BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) EVALUATION AND REIMBURSED PRICE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) COMBINATION DRUGS IN EU-3 (FRANCE, GERMANY, UNITED KINGDOM [UK])

    Nov 1, 2019, 00:00

  • PND17 SELECTING APPROPRIATE OUTCOME MEASURES FOR ALS CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PCN471 ATTITUDE TOWARDS CERVICAL CANCER SCREENING ATTENDANCE AND NON-ATTENDANCE AMONG ROMANY AND NON-ROMANY WOMEN

    Nov 1, 2019, 00:00

  • PCN416 NETWORK META-ANALYSIS FOR SURROGATE ENDPOINT EVALUATION IN ADVANCED COLORECTAL CANCER: A BAYESIAN APPROACH

    Nov 1, 2019, 00:00

  • PCN342 THE UPTAKE AND IMPACT OF THE EQ-5D-5L VALUE SET IN NICE TECHNOLOGY APPRAISALS WITHIN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS55 THE COST OF MEDICATION ERRORS IN PUBLIC HEALTH FACILITIES OF EASTERN REGION, GHANA.

    Nov 1, 2019, 00:00

  • PCV109 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS FOR THE MINIMALLY INVASIVE SUTURELESS AORTIC VALVE REPLACEMENT IN PATIENTS WITH AORTIC STENOSIS IN POLAND

    Nov 1, 2019, 00:00

  • PNS225 CURRENT STATUS OF OUTCOMES-BASED AGREEMENTS IN SELECTED EUROPEAN COUNTRIES AND CANADA

    Nov 1, 2019, 00:00

  • PCV55 COST-EFFECTIVENESS OF WARFARIN CARE BUNDLES AND NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION IN THAILAND

    Nov 1, 2019, 00:00

  • PMH14 THE BURDEN OF TREATMENT-RESISTANT DEPRESSION: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV70 HEALTH CARE COST FOR PATIENTS WITH CHRONIC HEART FAILURE AND IRON DEFICIENCY / ANEMIA BEFORE AND AFTER TREATMENT WITH FERRIC CARBOXYMALTOSE

    Nov 1, 2019, 00:00

  • PCN119 BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Nov 1, 2019, 00:00

  • PRO65 VARIABILITY IN AGE AT LOSS OF AMBULATION BY GENOTYPE AMONG BOYS WITH DUCHENNE MUSCULAR DYSTROPHY

    Nov 1, 2019, 00:00

  • PMU99 REVIEW OF RECENT NICE TECHNOLOGY APPRAISALS USING SIMULATED TREATMENT COMPARISONS

    Nov 1, 2019, 00:00

  • PCN166 ECONOMIC EVALUATION OF ANTICANCER DRUGS: A SYSTEMATIC REVIEW ON COST-EFFECTIVENESS STUDIES BASED ON HEALTHCARE SYSTEM CLAIMS DATABASES

    Nov 1, 2019, 00:00

  • PNS156 CHANGES IN LEADING CAUSES OF DEATHS AND THE NUMBER OF HOSPITAL BEDS IN HUNGARY BETWEEN 2002 AND 2017

    Nov 1, 2019, 00:00

  • PNS151 THE ROLE OF REGULATORY GUIDANCE AND INFORMATION DISSEMINATION FOR BIOSIMILAR MEDICINES - THE PERSPECTIVE OF HEALTHCARE PROFESSIONALS AND INDUSTRY

    Nov 1, 2019, 00:00

  • PND8 A SYSTEMATIC LITERATURE REVIEW OF EFFICACY AND SAFETY OF DISEASE MODIFYING THERAPIES (DMTS) IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN62 COMPARISON OF NETWORK META-ANALYSES USING STANDARD, MIXTURE CURE AND SPLINE MODELS

    Nov 1, 2019, 00:00

  • PDB99 UNDERSTANDING THE HUMANISTIC BURDEN AND PATIENT IMPACT IN NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PIN132 HEALTH-ECONOMIC MODELLING OF INFECTIOUS DISEASE DIAGNOSTICS: CURRENT APPROACHES AND FUTURE OPPORTUNITIES

    Nov 1, 2019, 00:00

  • PRS3 A SYSTEMATIC REVIEW OF SINGLE-INHALER TRIPLE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2019, 00:00

  • PDG10 IMPROVING THE BUSINESS MODEL OF VALUE ADDED MEDICINES: NEW VALUE ASSESSMENT FRAMEWORK IS NEEDED

    Nov 1, 2019, 00:00

  • PSY27 AN EXAMINATION OF THE BURDEN OF SICKLE CELL DISEASE AMONG ADULTS IN ENGLAND

    Nov 1, 2019, 00:00

  • PCN297 ATTRIBUTE DEVELOPMENT FOR A DISCRETE CHOICE EXPERIMENT (DCE) EXPLORING WILLINGNESS TO PAY (WTP) FOR CURING CANCER

    Nov 1, 2019, 00:00

  • PRS54 THE SUITABILITY OF THE EQ-5D-5L IN ASTHMA PATIENTS

    Nov 1, 2019, 00:00

  • PND103 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON WORK PRODUCTIVITY IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PCV75 COST ANALYSIS OF COMPLICATIONS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN TURKEY

    Nov 1, 2019, 00:00

  • PND97 FACTORS INFLUENCING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS USING EXPAND TRIAL DATA

    Nov 1, 2019, 00:00

  • PMU64 UNLOCKING ACCESS FOR TRANSFORMATIONAL CAR-T CELL AND GENE THERAPIES. ARE BIOSIMILARS THE KEY?

    Nov 1, 2019, 00:00

  • PDB68 ASSESSMENT OF RISK FOR DEVELOPMENT OF TYPE 2 DIABETES IN THE GREEK POPULATION

    Nov 1, 2019, 00:00

  • PPM3 GENOMIC SCREENING COSTS IN MODELLING: A PENALTY FOR INNOVATION?

    Nov 1, 2019, 00:00

  • PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

    Nov 1, 2019, 00:00

  • PUK11 TOLVAPTAN REDUCES HEALTHCARE BURDEN IN PATIENTS WITH STAGE 1-3 ADPKD IN SPAIN

    Nov 1, 2019, 00:00

  • PDG22 THE ECONOMIC IMPACT OF SERIOUS FLUOROQUINOLONE-RELATED ADVERSE EVENTS

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45 (current)
  • 46
  • 47
  • 48
  • 49
  • 50
  • »